New drug combo aims to wipe out hidden myeloma after transplant
NCT ID NCT04876248
First seen Nov 10, 2025 · Last updated Jun 13, 2026 · Updated 26 times
Summary
This study tests whether a combination of belantamab mafodotin (a targeted chemotherapy) and lenalidomide can eliminate any remaining cancer cells in multiple myeloma patients who still have detectable disease after a stem cell transplant. The trial enrolls 4 adults with multiple myeloma who are not cancer-free after transplant. The goal is to see if this treatment can achieve a negative minimal residual disease status, meaning no cancer cells are found using sensitive tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.